Published in Women's Health Weekly, January 13th, 2005
Pfizer Inc. has revealed results of a comprehensive six-year review of efficacy and safety data for DETROL LA (tolterodine tartrate extended release capsules) that indicate DETROL LA significantly reduces symptoms of overactive bladder (OAB) with a low occurrence of side effects, and should be considered first-line therapy. The results were recently published in the journal Drug Safety.
"We know that OAB is an important medical condition that can dramatically impact quality of life for some sufferers. Yet many...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly